Comparative Pharmacology
Head-to-head clinical analysis: CEFTIN versus ROCEPHIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTIN versus ROCEPHIN.
CEFTIN vs ROCEPHIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftin (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically transpeptidases, thereby disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily during active cell division.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with peptidoglycan cross-linking and leading to cell lysis.
250-500 mg orally twice daily for 10 days; for community-acquired pneumonia, 500 mg twice daily for 10 days. Intravenous: 750-1500 mg every 8 hours.
1-2 g IV or IM every 24 hours; maximum 4 g/day for serious infections.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (normal renal function); prolonged to 15-20 hours in severe renal impairment (CrCl <10 mL/min).
Terminal half-life ~6-8 hours in adults with normal renal function; prolonged to 12-24 hours in neonates and elderly.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal (33-67%) and biliary (40-50%); primarily excreted unchanged. Dual elimination: ~50% renal, ~50% biliary/fecal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic